Publication

Molecular imaging of estrogen receptors

van Kruchten, M., 2015, [Groningen]: University of Groningen. 165 p.

Research output: ThesisThesis fully internal (DIV)

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 874 KB, PDF document

  • Chapter 1

    Final publisher's version, 228 KB, PDF document

  • Chapter 2

    Final publisher's version, 5.28 MB, PDF document

  • Chapter 3

    Final publisher's version, 3.76 MB, PDF document

  • Chapter 3A

    Final publisher's version, 1.49 MB, PDF document

  • Chapter 4

    Final publisher's version, 1.29 MB, PDF document

  • Chapter 5

    Final publisher's version, 1.41 MB, PDF document

  • Chapter 6

    Final publisher's version, 5.73 MB, PDF document

  • Chapter 7

    Final publisher's version, 1.67 MB, PDF document

  • Chapter 8

    Final publisher's version, 1.67 MB, PDF document

  • Chapter 9

    Final publisher's version, 230 KB, PDF document

  • Supplemental files

    Final publisher's version, 577 KB, PDF document

  • References

    Final publisher's version, 397 KB, PDF document

  • Dankwoord

    Final publisher's version, 138 KB, PDF document

  • Publications

    Final publisher's version, 249 KB, PDF document

  • Complete dissertation

    Final publisher's version, 21.8 MB, PDF document

  • Propositions

    Final publisher's version, 48.7 KB, PDF document

  • Michel van Kruchten
For patients with estrogen receptor (ER) positive breast cancer, endocrine therapy plays a major role in both the adjuvant and palliative setting. For adequate treatment decision-making it is crucial to obtain up-to-date information on the ER-status of the tumor(s), since ER-expression is the sole predictor for response to endocrine therapy. Moreover, ER-status can change during the course of disease in up to 30% of the patients, and therefore treatments based on the ER-status of the primary tumor may be inadequate. Positron emission tomography (PET) imaging of ER-expression by use of the tracer 16α-[18F]fluoro-17β-oestradiol (FES) can give functional information about the ER-status of all lesions within the body. The aim of this thesis is to address the clinical potential of the FES-PET technique in breast and ovarian cancer patients.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date17-Jun-2015
Place of Publication[Groningen]
Publisher
Print ISBNs978-90-367-7944-9
Electronic ISBNs978-90-367-7943-2
Publication statusPublished - 2015

Download statistics

No data available

ID: 20137823